Skip to main content

Table 5 Summary of findings table for abacavir-containing cART regimens compared to cART regimens containing zidovudine or stavudine (RCTs)

From: Efficacy and safety of abacavir-containing combination antiretroviral therapy as first-line treatment of HIV infected children and adolescents: a systematic review and meta-analysis

Outcomes Illustrative comparative risks* (95 % CI) Relative effect (95 % CI) No of Participants (studies) Quality of the evidence (GRADE)
Assumed risk Corresponding risk
AZT or d4T - containing combination antiretroviral regimens ABC- containing combination antiretroviral regimens
Virologic suppression - ABC versus d4T (VL < 50–100 copies/ml) 688 per 1000 881 per 1000 RR 1.28 326
Follow-up: mean 48 weeks (461–1000) (0.67–2.42 (2 studies) moderatea
Adverse events 0 per 1000 0 per 1000 RR 2.41 81
Follow-up: mean 48 weeks (0–0) (0.1–57.52) (1 study) lowa,b
Death 0 per 1000 0 per 1000 RR 2.41 81
Follow-up: mean 48 weeks (0–0) (0.1–57.52) (1 study) lowa,b
  1. a Estimate of effect has a wide conference interval, including both a reduction and increase of effects
  2. b One study with a small number of participants
  3. * The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI)